IC
CLYM icon

Ikarian Capital’s Climb Bio CLYM Stock Holding History

Ikarian Capital’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.91M Buy
+300,000
New +$3.1M 0.42% 67
2025
Q2 		– Sell
-175,088
Closed -$214K – 194
2025
Q1 		$214K Hold
175,088
– – 0.03% 137
2024
Q4 		$315K Sell
175,088
-12
-0% -$43 0.04% 142
2024
Q3 		$891K Buy
175,100
+75,100
+75% +$531K 0.12% 100
2024
Q2 		$711K Buy
+100,000
New +$666K 0.12% 85

Other funds holding CLYM

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital's CLYM Position: Q2 2026 in Review

Ikarian Capital opened a new position in Climb Bio (CLYM) in Q2 2026: 300,000 shares worth $3.91M. The stake represents 0.42% of the portfolio and ranks #67 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in CLYM as recently as Q1 2025.

Ikarian Capital first reported a position in CLYM in Q2 2024 and has held it in 5 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Ikarian Capital held 300,000 shares of Climb Bio worth $3.91M as of Q2 2026.
  • Climb Bio was a new Ikarian Capital position in Q2 2026.
  • Climb Bio made up 0.42% of Ikarian Capital's portfolio in Q2 2026, its #67 holding.
  • Ikarian Capital first reported a position in Climb Bio in Q2 2024 and has held it in 5 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.